UNCY · Unicycive Therapeutics, Inc.
AI read · Good for UNCY
The AI's read
That brings OLC closer to a possible launch. The earlier FDA letter focused on manufacturing, not drug safety or whether it works, and the resubmission includes data from a new supplier. CMS's payment change may help providers use phosphate binders. Still, the FDA must approve OLC, and separate payments require CMS confirmation.